JDD Issue Highlights | May 2022
The May 2022 issue of the Journal of Drugs in Dermatology (JDD) focuses on skin cancer and features other topics such as fungal infections, updates on new topical advances, and Mohs micrographic surgery. We share this month’s issue highlights straight from the JDD Editor’s desk:
Insights in Skin of Color Patients With Atopic Dermatitis and the Role of Skincare in Improving Outcomes concludes …
The May 2022 issue of the Journal of Drugs in Dermatology (JDD) focuses on skin cancer and features other topics such as fungal infections, updates on new topical advances, and Mohs micrographic surgery. We share this month’s issue highlights straight from the JDD Editor’s desk:
Insights in Skin of Color Patients With Atopic Dermatitis and the Role of Skincare in Improving Outcomes concludes … 
Verruca vulgaris is a common cutaneous manifestation of Human Papillomavirus (HPV) infection that presents as hyperkeratotic, cauliflower-like papules with central black petechiae. These lesions may be resistant to conventional therapies, posing a therapeutic challenge and prolong significant morbidity for the patient. This case report demonstrates an immediate and robust response of recalcitrant … 
The April 2022 issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, case reports, and editorials. With topics ranging from injectable fillers, botulinum toxin in hidradenitis suppurativa, cannabis and cannabinoid product use, to psoriasis, melasma, onychomycosis and everything in between, we share this month’s issue highlights straight from the JDD … 
Telogen effluvium (TE) – a common cause of non- scarring hair loss – is managed with varying clinical protocols given the paucity of evidence-based practices.
INTRODUCTION
Telogen effluvium (TE) – a common cause of non-scarring hair loss – is managed with varying clinical protocols given the paucity of evidence-based practices. While endocrine, vitamin, and mineral abnormalities … 
Hydroquinone is the most commonly used depigmentation agent and is a first-line treatment for melasma.1Hydroquinone was available previously in over-the-counter products and is currently available in prescription formulations with common concentration ranges of 0.4 to 5%. Prescription strengths available in the United States include hydroquinone 2% and 4% cream and hydroquinone 2% gel.2,3 In Septe … 